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Abstract                                                                                                                                                                                                                                                                                                                                                                                                                                           
BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is an important cause of severe liver 
disease and is associated with both quantitative and qualitative regulatory T cell (Treg) impairments. 
We have shown that Tregs express CD39, an ectonucleotidase responsible for extracellular nucleotide 
hydrolysis, culminating in the production of immunosuppressive adenosine. In this study, we describe 
multiple CD39pos Treg defects that potentially contribute to the impaired immuno-regulation that is 
characteristic of AIH. METHODS: We have examined the frequency and phenotype of CD39pos Tregs 
by flow cytometry and measured their ectonucleotidase activity. The capacity of CD4posCD25high, 
CD4posCD25highCD39pos and CD4posCD25highCD39neg subsets to suppress both proliferation of effector 
T cells and IL17 production was evaluated.  RESULTS: In AIH, CD39pos Tregs are decreased in 
frequency, exhibit limited adenosine triphosphate (ATP)/adenosine diphosphate (ADP) hydrolysis 
activity and fail to suppress IL17 production by effector CD4 T cells. Moreover, these CD39pos Tregs 
display a more pro-inflammatory profile in AIH, which is characterised by elevated CD127 positivity, 
and a greater propensity to produce IFNγ or IL17 upon challenge with pro-inflammatory stimuli. 
CONCLUSIONS: In AIH CD39pos Tregs are decreased in number, fail to adequately hydrolyse pro-
inflammatory nucleotides and do not suppress efficiently IL17 production by effector CD4 T cells. 
CD39pos Tregs show plasticity and are unstable upon pro-inflammatory challenge, suggesting that 
defective immuno-regulation in AIH might result not only from reduced Treg number and function 
but also from increased conversion of Tregs into effector cells.   
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Introduction 
Autoimmune hepatitis (AIH) is an inflammatory disease of the liver, characterised by female 
preponderance, interface hepatitis on histology, hypergammaglobulinaemia and serum autoantibody 
positivity(1, 2). Several lines of evidence indicate that in AIH numerical and functional regulatory T 
cell (Treg) defects are likely to play a permissive pathogenic role, allowing effector CD4 and CD8 T 
lymphocytes to initiate and perpetuate liver damage(3-5). 
The reasons for the Treg functional impairment in AIH are unclear. Previous studies in both mice and 
humans have highlighted a number of mechanisms used by Tregs to mediate suppression, including 
the release of anti-inflammatory cytokines and the modulation of antigen presenting cell function.   
More recently, metabolic disruption of effector cell function by Tregs has also been explored(6). 
Central to this mode of suppression is the expression by Tregs of the ectoenzyme CD39, which 
catalyses the degradation of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) into 
adenosine monophosphate (AMP). AMP is subsequently converted to the immunomodulatory 
nucleoside adenosine by CD73, an ectoenzyme that works in tandem with CD39(7-9). 
At variance with the murine setting, CD39 in humans is expressed not only by conventional Tregs but 
also by cytokine - i.e. IL4, IL5, IL17 and IFNγ - producing effector memory cells(8, 10). Again unlike 
mice, CD73 is poorly expressed by human Tregs, suggesting that in humans AMP conversion to 
adenosine is mediated by paracrine mechanisms or by the presence of CD73 on target or neighbouring 
cells(10).  
Compared to their CD39neg counterpart, CD39pos Tregs have been shown to be phenotypically stable 
upon pro-inflammatory challenge(10) and to display preferential suppression over Th17 
immunity(11). 
Defective numbers of CD39pos Tregs have been reported in patients with multiple sclerosis(8, 11), 
where these cells are also impaired in their ability to suppress IL17 production(11). Defective CD39pos 
Treg function has been also described in systemic lupus erythematosus(12). Additionally, the 
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presence of a CD39 single nucleotide polymorphism has been reported in Crohn’s disease and found 
to be associated with low CD39 mRNA expression levels and disease susceptibility(13). 
Given the key role of CD39 in governing Treg suppressive function, we aimed to explore whether the 
impairment of Tregs, previously observed in AIH, resided in alterations of CD39 expression. To this 
end, we investigated the frequency, phenotypic and functional signature of CD39pos Tregs in AIH as 
well as their stability upon pro-inflammatory challenge, a feature particularly relevant to the 
development of immunotherapeutic strategies aimed at reconstituting immuno-tolerance through Treg 
adoptive transfer. 
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Patients and methods 
Patients and controls 
Forty-one patients with anti-nuclear and/or anti-smooth muscle antibody positive AIH (25 female) 
were studied. At the time of, or close to diagnosis a liver biopsy showed interface hepatitis in all. 
Patients with bile duct changes characteristic of sclerosing cholangitis on retrograde cholangiography 
were excluded from analysis. The median age of patients included in the study was 14 years (range 6-
27 years). Of fourteen patients with active disease, defined by the presence of abnormal aspartate 
aminotransferase (AST) levels, three were studied before immunosuppressive treatment was started. 
Twenty-seven patients were studied during drug-induced remission (defined by normalisation of AST 
levels). Treatment consisted of prednisolone (5-15mg/day) with or without azathioprine (25-
150mg/day) or mycophenolate mofetil (MMF; 500-2000mg/day, n=10). Demographic and 
biochemical data are shown in Table 1. Eight subjects with liver disorders of non-autoimmune and 
non-viral aetiology served as disease control patients (DC) (7 females, median age 15 years [range 6-
25 years]). Of this group, two patients had non-alcoholic fatty liver disease (NAFLD), one α-1 
antitrypsin deficiency, one Gilbert syndrome, one Wilson disease, one congenital portosystemic shunt, 
one Alagille syndrome and one hepatic adenoma. Twenty-five healthy subjects (HS) served as normal 
controls (15 females, median age 35 years [range 22-50 years]). The age difference between AIH/DC 
patients and HS derived from ethical constraints in obtaining blood from healthy children. The study 
was approved by the ethical committee of King’s College Hospital, London and written consent was 
obtained from each AIH patient and HS enrolled in the study. 
Cell separation 
Peripheral blood mononuclear cells (PBMCs) were isolated as described previously (3). Viability of 
mononuclear cells, determined by trypan blue exclusion, exceeded 98%.  
Flow cytometry 
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PBMCs were stained with allophycocyanin (APC) cychrome-7 (Cy7)-conjugated anti-CD4, APC-
conjugated anti-CD73, phycoerythrin (PE)-Cy7-conjugated anti-CD39 (all eBioscience, Hatfield, 
UK), PE-conjugated anti-CD25, fluorescein isothyocyanate (FITC)-conjugated anti-CD127, PE-
conjugated anti-CD45RO and FITC-conjugated anti-CD62L (all BD Biosciences, Discovery Labware, 
Oxford, UK) monoclonal antibodies. Cells were incubated at 4°C in the dark for 30 minutes and 
washed with phosphate buffered saline (PBS) supplemented with 1% foetal calf serum (FCS) before 
analysis by flow cytometry on a Becton Dickinson fluorescence activated cell sorter (FACS-Canto™ 
II, Beckton Dickinson Immunocytochemistry Systems, San Jose, CA). FACSDiva software was used 
for analysis. The percentage of cells positive for FOXP3 or intracellular CD152 was determined after 
fixation and permeabilisation with Cytofix/Cytoperm™ (BD Biosciences) and the addition of APC-
conjugated anti-FOXP3 (eBioscience) or APC-conjugated anti-CD152 (BD Biosciences) monoclonal 
antibodies.  
The percentage of IFNγ, IL17, IL10 and transforming growth-factor β (TGFβ)-positive cells was 
determined after exposure to phorbol 12-mystrate 13-acetate (10ng/mL) and ionomycin (500ng/mL; 
both Sigma Aldrich, Gillingham, UK) and following addition of brefeldin-A (10µg/mL; Sigma 
Aldrich) for 5 hours. Cells were then stained using PE-conjugated anti-IFNγ, PE-conjugated anti-IL10 
(both BD Biosciences), FITC-conjugated anti-IL17 (eBioscience) or Peridinin chlorophyll protein 
complex (PerCP)-conjugated anti-TGFβ (R&D Systems, Abingdon, UK).  
Cell stimulation 
PBMCs were seeded at 1×106 cells/ml in 96-well round-bottom plates in RPMI-1640 pre-
supplemented with 2mM L-glutamine and 1% Antibiotic-Antimycotic solution (both from Gibco, 
Invitrogen, Paisley, UK) and 10% FCS. Cells were exposed to anti-CD3/anti-CD28 T cell expander 
(ratio bead/cell: 1/2; Dynal Invitrogen, Oslo, Norway) and recombinant human IL-2 (30U/mL; 
EuroCetus; Amterdam, Netherlands), a protocol chosen on the basis of previous experiments(14). To 
test whether the phenotype of CD39pos Tregs remained stable upon pro-inflammatory challenge, cells 
were treated with recombinant human IL6 (0.04µg/mL) and IL1β (0.01µg/mL; both R&D Systems) 
7 
	
and cultured at 37°C and 5% CO2 for 5 days. Cells were washed in PBS/1% FCS and flow cytometry 
was performed as above. 
Cell purification 
For co-culture assays, CD4pos cells were isolated from the total PBMC population using 
immunomagnetic beads (Dynal Invitrogen) as described(3, 14). CD4pos T cells were then stained with 
FITC- or APC-Cy7-conjugated anti-CD4 (eBioscience), APC- or PE-conjugated anti-CD25 (BD 
Bioscences) and PE- or PE-Cy7-conjugated CD39 (eBioscience). The CD4pos cells were then sorted 
into CD25high, CD25highCD39pos (CD39pos Tregs), CD25highCD39neg (CD39neg Tregs) and CD25neg 
subsets by fluorescence activated cell sorting (FACS) using a Becton Dickinson cell sorter 
(FACSAria™ II; Beckton Dickinson Immunocytochemistry Systems). The purity of the CD25high, 
CD25highCD39pos and CD25highCD39neg populations exceeded 95% and the purity of the CD25neg cells 
exceeded 98%.  
For experiments assessing CD39 enzymatic activity, CD4posCD25pos and CD4posCD25neg populations 
were isolated immunomagnetically as described previously(3, 14). The purity of immunomagnetically 
isolated populations exceeded 85%. 
Measurement of enzymatic activity 
The enzymatic activity of immunomagnetically isolated CD4posCD25neg and CD4posCD25pos cells was 
measured indirectly by quantifying the concentration of free phosphate using the colorimetric 
Sensolyte® malachite green phosphate assay kit (AnaSpec, Seraing, Belgium). Populations were 
washed in saline solution containing 0.9% w/v NaCl – to remove residual phosphate-containing media 
– and plated at 2×105 cells/ml, before exposure to 10µM ATP (Sigma Aldrich, Gillingham, UK) for 
15 minutes. Phosphate concentration was quantified at 600nm using an absorbance plate reader after 
comparison with a standard curve. 
Thin layer chromatography (TLC) was performed as described previously(7), to visualise the 
hydrolysis of radiolabeled ADP to AMP and its subsequent conversion to adenosine. 2.5×105 
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immunomagnetically isolated CD4posCD25pos or CD4posCD25neg cells were exposed to 2mCi/ml [C14] 
ADP (Perkin Elmer, Cambridge, UK) in the presence of 10mM Ca2+ and 5mM Mg2+. Aliquots were 
collected at reaction-times of 5, 10, 20, 40 and 60 minutes before analysis of [C14]ADP hydrolysis 
products by TLC. Samples were loaded onto silica gel matrix plates (Sigma Aldrich, Gillingham, UK) 
and [C14]ADP derivatives were separated using an appropriate solvent mixture(15). 
Co-culture assays 
Once purified, the CD25neg responder cell populations were seeded overnight in 96-well round-bottom 
plates in the presence of anti-CD3/anti-CD28 T cell expander (ratio bead/cell: 1/2 Dynal Invitrogen) 
and recombinant human IL2 (30 U/mL; EuroCetus). CD25high, CD39pos or CD39neg Tregs were then 
added to autologous CD25neg responder cells at a ratio of 1/8(14). Parallel cultures of CD25neg 
responder cells in the absence of Tregs were performed. To analyse the proliferation of effector cells, 
for the final 18 hours of culture, cells were pulsed with 0.25µCi/well 3H-thymidine (Perkin Elmer, 
Cambridge, UK) and harvested using a multichannel harvester. The amount of incorporated 3H-
thymidine was measured using a β-counter. In preliminary experiments, in which cells from 4 AIH 
patients and 4 HS were tested, proliferation was also analysed using the CellTrace™ carboxy 
fluorescein succinimidyl ester (CFSE) cell proliferation kit (Molecular Probes, Paisley, UK). For 
analysis of cytokine production, cells were stained with FITC- or APC-Cy7-conjugated anti-CD4, 
FITC- or PE- conjugated anti-IL17 (all eBioscience) and APC- or PE- conjugated anti-IFNγ (IQ 
Products, Netherlands, and BD Biosciences) and analysed as described above.  
Statistical analysis 
The normality of variable distribution was assessed by the Kolmogorov-Smirnov goodness of fit test; 
once the hypothesis of normality was accepted (P<0.05), comparisons were performed using paired or 
unpaired Student’s t tests for linked or unlinked data respectively. A one-way ANOVA, followed by 
Tukey’s multiple comparisons test, was used to compare the means of multiple samples. Results are 
expressed as mean±SEM unless otherwise stated and P values <0.05 were considered significant. P 
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values ≥0.05 and ≤0.15 denote a trend to significance. Data were analysed using GraphPad Prism® 5 
software (GraphPad; San Diego, CA) and SPSS software (IBM; Hampshire, UK). 
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Results 
Enumeration and characterisation of CD4posCD25highCD39pos regulatory T cells  
The frequency of circulating CD4posCD39pos cells was similar in AIH patients, DC patients and HS 
(9.7±2.7, 10.8±2.4 and 11.1±2.0 respectively, P=NS). However, the frequency of 
CD4posCD39posCD25high (hereafter denoted CD39pos Tregs) was markedly reduced in AIH patients 
compared to DC patients or HS (Figure 1A,B). The frequency of CD39pos Tregs was similar in AIH 
patients with active and inactive disease (4.2±1.3 vs 3.5±0.7, P=NS). Male AIH patients had fewer 
CD39pos Tregs compared to their female counterparts (2.4±0.6 vs 5.1±0.9, P=0.03). The difference 
between males and females was not observed in the HS population (9.4±2.8 vs 6.8±1.8, P=NS). To 
test the influence of age on the frequency of CD39pos Tregs, AIH patients were subdivided into those 
<13 or ≥13 years of age. The frequency of CD39pos Tregs did not differ when this comparison was 
made (4.7±1.4 vs 3.3±0.3, P=NS). CD25high cells contained higher proportions of cells positive for 
CD39 compared to the CD25medium(med) and CD25neg populations in  HS [CD25high: 43.0±4.8 vs 
CD25med: 26.0±5.3 (P<0.05) and vs CD25neg: 14.6±3.2 (P<0.001)], DC patients [CD25high: 46.7±8.4 vs 
CD25med: 23.4±3.6 (P<0.05) and vs  CD25neg: 15.2±3.5 (P<0.01)] and AIH patients [CD25high: 
40.7±4.6 vs CD25med: 22.8±3.8 (P<0.05) and vs CD25neg: 12.6±2.6 (P<0.001)]. In AIH patients, DC 
patients and HS, the frequency of CD4posCD39pos cells positive for FOXP3 was greater in the CD25high 
subset compared to the CD25med or CD25neg populations (Figure 1C).   
AIH patients treated with prednisolone and MMF had a lower frequency of CD39pos Tregs compared 
to those treated with prednisolone alone (5.6±1.9 vs 1.7±0.5, P=0.01) or with prednisolone and 
azathioprine (4.7±1.1 vs 1.7±0.5, P=0.03).  
Compared to HS and DC patients (Table 2), CD39pos Tregs from AIH patients contained a lower 
frequency of cells negative for CD127 – the lack of which distinguishes bona fide Tregs from effector 
T cells(16, 17) – , lower proportions of cells positive for the memory cell marker CD45RO and a 
similar frequency of cells positive for the Treg function-associated markers FOXP3, CD152 or 
CD62L. Approximately 10% of CD39pos Tregs expressed CD73 in AIH patients, DC patients and HS.  
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The frequency of CD127neg cells within CD39pos Tregs tended to be lower in patients with active 
disease compared to those studied during remission (Table 2). 
The frequency of CD39pos Tregs producing the pro-inflammatory cytokines IFNγ and IL17 or the anti-
inflammatory cytokines TGFβ or IL10 was similar in AIH patients, DC patients and HS (Table 2). 
Given that the frequency and the phenotype profile of CD39pos Tregs in HS and DC patients were 
comparable, only cells from HS were used for the following experimental sections. 
Phenotypic stability of CD39pos regulatory T cells 
After stimulation of PBMCs with anti-CD3/anti-CD28 T cell expander (Table 3a), the frequency of 
CD39pos Tregs positive for FOXP3 or CD127 increased to a similar extent in AIH patients and HS. 
The frequency of CD73pos CD39pos Tregs decreased and the frequency of CD45ROpos CD39pos Tregs 
increased in HS, while remaining unchanged upon stimulation in AIH patients. The frequencies of 
IFNγ and IL17-producing cells within CD39pos Tregs remained stable in HS, while increased in AIH 
upon stimulation. The increase in the frequency of CD39pos Tregs expressing IL17 or IFNγ was 
greater in AIH patients compared to HS (Table 3a).  
Interestingly, in AIH the size of the increase in frequency of IFNγpos CD39pos Tregs correlated with 
serum AST concentration (r2=0.82, P<0.05).   
Exposure of PBMCs to IL1β and IL6 (Table 3b) increased the frequency of FOXP3pos CD39pos Tregs 
in HS but not AIH patients, but had no effect on the frequency of CD39pos cells expressing CD127 or 
CD45RO. The frequency of CD73pos CD39pos Tregs decreased significantly in HS, while it increased 
in AIH patients, though not significantly. While the frequency of CD39pos Tregs producing IFNγ 
increased to a similar extent in both AIH patients and HS, the frequency of those producing IL17 
increased in AIH but remained stable in health.  
ATP/ADP hydrolysis 
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Immunomagnetically isolated CD4posCD25pos Tregs from AIH patients were less able to hydrolyse 
exogenous ATP compared to HS (Figure 2A). In HS, but not AIH patients, the CD25pos cells 
generated greater concentrations of phosphate compared to CD25neg cells (Figure 2A), as and this was 
reflected by higher CD39 expression on a population (3.65±0.40 vs 24.53 ±4.61, P=0.002) and per-
cell basis, the latter expressed as mean fluorescence intensity (2239±147 vs 2901±213, P=0.059).  
Analysis of [C14]-radiolabelled ADP hydrolysis by TLC (Figure 2B) revealed that CD4posCD25pos 
cells from HS were able to hydrolyse ADP into AMP and, at the longer reaction time of 60 minutes, 
these cells could generate extracellular nucleosides. 
In contrast, AMP generation was less pronounced in CD4posCD25pos cells from AIH patients. 
CD4posCD25neg cells in health and AIH degraded ADP less efficiently than the CD4posCD25pos 
populations, failing to produce extracellular adenosine.  
Suppressive ability of CD39pos Tregs 
Preliminary experiments, in which both 3H-thymidine and CFSE were used to analyse the suppressive 
ability of immunomagnetically isolated CD4posCD25pos cells, confirmed reports(3, 4, 14) that Tregs 
from AIH patients are less able to suppress the proliferation of autologous CD4posCD25neg responder 
cells compared to HS (Supplementary Figure 1). As CFSE- and 3H-thymidine-based assays gave 
comparable results, given the requirement for fewer cells, 3H-thymidine was used to measure the 
proliferation of FACS sorted populations, which had comparatively low yield compared to those 
magnetically isolated.  
CD4posCD25high Tregs from HS and AIH patients and CD39neg Tregs from HS were able to suppress 
the proliferation of responder T cells (one-sample t-tests when comparing suppression in the presence 
and absence of Tregs; P=0.04, P=0.04, P=0.05 respectively. Percent suppression of proliferation by 
CD25high cells was lower in AIH patients than in HS. In HS, CD39pos Tregs were poor suppressors of 
proliferation compared to conventional CD4posCD25high Tregs and CD39neg Tregs (Figure 3A).  
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In HS, CD4posCD25high, CD39pos and CD39neg Tregs were able to suppress the production of IL17 (one 
sample t-tests; P=0.001, P=0.01, P=0.007 respectively), while in AIH, only the CD25high population 
was able to suppress IL17 production (one sample t-test; P=0.006). Both the CD25high and CD39pos 
Tregs were less able to suppress IL17 production in AIH patients compared to HS (Figure 3B).  
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Discussion 
In the current study we show that Tregs expressing the ectonucleotidase CD39 are present at low 
levels and are also dysfunctional in AIH. 
Phenotypic analysis has indicated that the expression of CD39 is associated with classical Treg 
features, i.e. high CD25 and FOXP3 and low CD127 expression. CD39pos Tregs effectively suppress 
CD4 T cell IL17 production while exerting poor control over target cell proliferation, suggesting that 
this Treg subgroup may have a specific role in dampening Th17 immunity. Low frequencies of 
CD39pos Tregs and inability to control adequately IL17 mediated immuno-reactivity have been 
described also in patients with MS (8, 11). Moreover, low CD39 expression has been reported in IBD, 
where it is associated to a CD39 polymorphism (13), suggesting a genetically encoded defect of 
immune regulation in this condition. Future studies should explore whether CD39 polymorphisms 
account for the observed Treg/effector cell imbalance in AIH, and therefore contribute to disease 
initiation and/or perpetuation.  
A comparison between health and disease has revealed that CD39pos Tregs from AIH patients are 
impaired in number, in their ability to hydrolyse ATP and ADP and in their suppressive function, 
indicating that in AIH CD39pos Treg impairment occurs at multiple levels.  
A potential limitation of this study is the use of a heterogenous AIH population, including patients 
under different treatment regimens. This has been overcome to some extent by the size of the patient 
group which has enabled us to observe interesting and novel associations. We have, for example, 
noted that the frequency of CD39pos Tregs was markedly decreased in AIH patients receiving 
prednisolone and MMF compared to those treated with prednisolone alone or in combination with 
azathioprine, raising the possibility that these treatment regimens differentially impact the frequency 
of this regulatory T cell subset. Alternatively, the lower CD39pos Treg frequencies observed in the 
MMF treated group may reflect the fact that these patients have a particularly severe form of disease 
characterised by a more marked impairment in immune-regulation and the mechanisms governing it. 
Also of note, CD39pos Treg defects were particularly pronounced in male AIH patients. Since this 
15 
	
gender difference was not observed in healthy subjects, it is possible that hormonal differences, 
particularly the presence of oestrogen, can partially overcome the CD39pos Treg defect in AIH.  
In AIH patients, particularly in those with active disease, CD39pos Tregs contain low proportions of 
CD127neg lymphocytes, suggesting that CD39pos Tregs from AIH patients, in addition to being 
numerically defective, are also skewed towards a pro-inflammatory profile. Lower CD127neg cell 
frequencies within CD39pos Tregs are paralleled by lower proportions of CD45ROpos cells. Though the 
reasons for the CD45RO decrease are unclear, it should be recalled that in humans CD39 is mainly 
expressed on memory cells(10); therefore low frequencies of CD45ROpos lymphocytes may reflect the 
numerical CD39pos Treg impairment.  
In AIH, CD39pos Tregs are also less able to hydrolyse ATP and ADP, this defect ultimately resulting 
in reduced production of AMP and immunosuppressive adenosine. Persistently high levels of pro-
inflammatory ATP and ADP may contribute to the perpetuation of inflammation. Inefficient CD39 
hydrolytic activity is likely to account for the decreased ability of Tregs to control CD4 effector cell 
function, in particular the production of IL17, which is involved in AIH liver damage(18, 19). 
Expression of CD39 has previously been linked to Treg lineage stability(10, 11). Characterisation of 
CD39pos Treg phenotype before and after stimulation with anti-CD3/anti-CD28, a classical T cell 
stimulus, and with IL6 and IL1β, cytokines mimicking the pro-inflammatory environment in AIH, has 
shown that CD39pos Tregs from AIH patients are less stable than in health, as they undergo a marked 
increase in the production of IL17 and IFNγ. These data suggest that Treg impairment in AIH might 
derive from an increased rate of Treg conversion into effector cells (Figure 4).  
Of note, in contrast to HS, CD73 expression by CD39pos Tregs in AIH patients remained elevated 
after pro-inflammatory challenge. That CD73 is strictly linked to activation was previously shown in a 
study by Doherty et al, who reported high CD73 expression levels on CD4 T cells from Crohn’s 
patients with more active disease(20).  
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The findings of a reduced stability of CD39pos Tregs in AIH patients should be taken into 
consideration when developing immunotherapeutic strategies aimed at re-establishing immune-
homeostasis through adoptive Treg transfer. Thus, protocols for Treg expansion should include 
treatment with agents/molecules (e.g. retinoic acid and/or rapamycin) aimed at boosting Treg 
properties while inhibiting their conversion to pathogenic Th1 and Th17 effector cells. Since CD39pos 
Tregs exhibit potent IL17-suppressive properties in health, possible mechanisms for boosting CD39 
expression in AIH should be explored. A potential candidate is retinoic acid, which is able to boost 
CD39 expression by naïve T cells (Robson, unpublished observation). 
Previous investigations have shown accumulation of CD39pos Tregs in the liver of patients with 
chronic hepatitis B infection (21). In the experimental cancer setting, hepatic growth of melanoma 
metastatases is inhibited in CD39null mice, while CD39pos T-regs inhibit anti-tumour immunity (22). 
Future studies should examine the frequency and the tissue localisation of liver infiltrating CD39pos 
Tregs in AIH and explore whether defective CD39 expression by circulating Tregs is also reflected in 
the inflamed liver. These findings would have important implications for the development of adoptive 
Treg therapy for AIH.  
In conclusion, this study has shown that in AIH there is a numerical decrease in CD39pos Tregs. These 
CD39pos Tregs are impaired in their enzymatic and suppressive abilities and, upon pro-inflammatory 
challenge, are less stable than in health. Defective immune-regulation in AIH may derive not only 
from impaired Treg number and function but also from an increased rate of Treg conversion into 
effector cells. 
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Legends to figures  
Figure 1. Characterisation of CD39pos Tregs. (A) Frequency of CD4posCD25highCD39pos Tregs in 
one representative autoimmune hepatitis (AIH) patient, one disease control (DC) patient and one 
healthy subject (HS). Plots show gated CD4pos lymphocyte populations. (B) Frequency of 
CD4posCD25highCD39pos Tregs in 31 AIH patients, 8 DC patients and 25 HS. (C) Frequency of 
FOXP3pos cells within CD4posCD39posCD25high, CD4posCD39pos CD25med and CD4posCD39posCD25low 
populations in 31 AIH patients, 8 DC patients and 25 HS.  
Figure 2. CD39 enzymatic activity of Tregs in AIH and HS. (A) Ability of immunomagnetically 
isolated CD4posCD25pos and CD4posCD25neg cells from 3 autoimmune hepatitis (AIH) patients and 4 
healthy subjects (HS) to produce free phosphate – the bi-product of ATP hydrolysis – after the 
addition of exogenous ATP. (B) CD39 ADPase enzymatic activity of immunomagnetically isolated 
CD4posCD25pos and CD4posCD25neg cells was assessed by thin layer chromatography at 5, 10, 20, 40 
and 60 minute time-points following incubation with 14C-radiolabelled ADP substrate. Image 
representative of 3 independent experiments.  
Figure 3. Suppressive ability of CD39pos Tregs. The ability of FACS-sorted CD4posCD25high, 
CD4posCD25highCD39pos  and CD4posCD25highCD39neg Treg populations  to suppress the proliferation 
(A) or IL17 production (B) of CD4posCD25neg responder cells. For suppression of proliferation, data 
refer to 4 healthy subjects (HS) and 4 autoimmune hepatitis (AIH) patients. For suppression of IL17 
production, data refer to 6 HS and 10 AIH patients. 
Figure 4. Impairment of CD39pos Tregs in AIH. In health, CD39pos Tregs produce adenosine and 
adequately control autoreactive T cell effector functions. In AIH, multiple CD39pos Treg defects – a 
reduction in frequency, an inability to suppress IL17 production by effector cells, and a propensity to 
convert to IFNγ or IL17 producing effectors – contribute to impaired immunosuppression and 
autoimmune liver damage.  
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